Komori
Fuji Pharma (4554) · RiskRestated

Risk of declining market prices due to competition with other companies in the same industry

First written in FY2017. 1 of 4 entries say "Materialised", first in FY2019. Latest entry: FY2022.

4entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2017MaterialisedFY2019MitigatedFY20212017: 12018: 020182019: 120192020: 020202021: 120212022: 12022
Same theme, other companies
Declining selling prices and lower profits due to intensifying competition with other companiesA theme 226 companies write about · 227 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 41 of 85 companies on the "Worse" side.

106 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 227 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「As measures, the Company is implementing cross-functional initiatives to secure cost competitiveness, including reducing raw-material procurement costs and cutting costs by reviewing manufacturing methods.」

    The Company continues to address the risk of declining market prices due to competition and cost measures through reviews of raw-material procurement and manufacturing methods.
  2. FY2021MitigatedAnnual report

    「As measures, the Company is implementing cross-functional initiatives to secure cost competitiveness, including reducing raw-material procurement costs and cutting costs by reviewing manufacturing methods.」

    While continuing to disclose the risk of declining market prices due to competition, the Company has specified cross-functional cost measures, including reviewing raw-material procurement and manufacturing methods.
  3. FY2019MaterialisedAnnual report

    「The main reasons were a decline in revenue resulting from the discontinuation of development of products under development, the transfer of branded contrast media, including Optiray, and a decline in the market share of core products due to the launch of generic products by other companies.」

    The launch of generic products by other companies is identified as an actual factor behind the decline in the market share of core products and the resulting decline in revenue.
  4. FY2017First statedAnnual report

    「For some products, intense competition among numerous manufacturers may cause market prices to fall substantially. In addition, measures taken by domestic manufacturers of new drugs to secure market share may prevent the Group from achieving its planned budget.」

    The risks to market prices and budget achievement arising from competition with numerous manufacturers and measures taken by domestic manufacturers of new drugs are stated.
Moved together

"Greater Uncertainty in the Macroeconomic and Global Environment" moved the same way as this thread, in the same document, in 2 of its 4 moves.

2★1
  1. ★This thread
  2. 1Greater Uncertainty in the Macroeconomic and Global Environment2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Fuji Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of declining market prices due to competition with other companies in the same industry | Fuji Pharma Co.,Ltd. (4554) | Komori